Viking Therapeutics stock forecast: Third-party price targets
Viking Therapeutics is a US-listed clinical-stage biotechnology company whose share price reflects developments in its drug pipeline, company disclosures and wider conditions in the biotech sector. Explore third-party VKTX price targets and technical analysis.
Viking Therapeutics, Inc. (VKTX) is trading around $29.11 in intraday action on 2 February 2026, moving within a session range of $28.92–$30.38 on Capital.com’s feed as of 4:36pm UTC. Past performance is not a reliable indicator of future results.
The price action comes amid ongoing focus on Viking’s metabolic pipeline, including its dual GLP-1/GIP receptor agonist VK2735 (PR Newswire, 8 January 2026). The company has recently highlighted continued Phase 3 obesity studies and maintenance-dosing work, alongside prior Phase 2 VENTURE data that showed improvements in cardiometabolic markers (Investing.com, 8 January 2026). Traders are also monitoring corporate developments such as insider transactions reported in early January 2026, as well as expectations around upcoming fourth-quarter 2025 results scheduled for early February, which may influence liquidity and news flow around the earnings release (MarketBeat, 28 January 2026).
Viking Therapeutics stock forecast 2026–2030: Third-party price targets
As of 2 February 2026, third-party Viking Therapeutics stock predictions show a wide dispersion of 12-month expectations, reflecting differing views on the company’s obesity and liver-disease pipeline. The following third-party forecasts summarise recently published targets and underlying assumptions available as of January–February 2026.
Investing.com analysis (biotech focus article)
An Investing.com feature on biotech stocks to watch states that analysts have a consensus price target of $87.14 on VKTX, described as implying roughly 155% upside from the mid-January closing level. The article links this view to potential outcomes for Viking’s obesity drug candidate and the possibility that successful late-stage data could make the firm a takeover candidate, while also stressing clinical and execution risks (Investing.com, 20 January 2026).
Zacks (brokerage recommendation summary)
Zacks highlights that Viking Therapeutics has an average brokerage recommendation of 1.22 on a 1–5 scale and summarises Street expectations for upside from prevailing prices, without specifying a single numeric target. The report says this assessment reflects brokers’ focus on Viking’s R&D pipeline potential and the uncertainty typical of clinical-stage biotech names (Zacks, 8 January 2026).
Stockscan.io (quantitative aggregator model)
Stockscan.io states that its February 2026 VKTX stock forecast embeds an average 2026 value near $284.63 per share, with a projected range between roughly $236.25 and $333.01, and a separate 12-month target around $299.68. The site attributes these figures to a model-based outlook that assumes substantial upside from current levels, based on expectations of continued development progress and positive momentum signals (Stockscan.io, 2 February 2026).
MarketBeat (earnings preview and consensus)
MarketBeat notes that analysts covering Viking Therapeutics hold a consensus rating of 'Moderate Buy' and a consensus 12-month target price of $87.14 as of that date. The piece frames this objective in the context of expectations for the company’s fourth-quarter 2025 results and highlights the stock’s 12-month trading range and sector risk profile (MarketBeat, 28 January 2026).
Predictions and third-party forecasts are inherently uncertain, as they cannot fully account for unexpected market developments. Past performance is not a reliable indicator of future results.
VKTX stock price: Technical overview
The VKTX stock price is trading around $29.11 as of 4:36pm UTC on 2 February 2026, sitting below its key daily moving-average cluster, with the 20-, 50-, 100- and 200-day simple moving averages grouped near 31.9, 34.4, 33.2 and 31.2, respectively. Momentum appears soft rather than extreme, with the 14-day RSI around 35.7 in lower-neutral territory and the ADX near 13.7, indicating a weak, non-trending backdrop.
On the topside, the first area to watch is the classic R1 pivot at 33.8, above the 31.4 pivot point. A sustained daily close through R1 would bring the R2 region near 38.6 back into view and refocus attention on the broader moving-average band. On pullbacks, initial support aligns with the classic pivot at 31.4, followed by the nearby 100-day SMA around 33.2, while a break below the S1 zone near 26.6 could expose the deeper 24.2 support band highlighted by S2 (TradingView, 2 February 2026).
This technical analysis is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any instrument.
Viking Therapeutics share price history (2024–2026)
VKTX’s stock price has experienced pronounced swings over the past two years, moving from the low-$20s to almost $100 before sliding back under $30 by early 2026. After trading around $24–$32 in February 2024, VKTX surged through the spring and summer, peaking near $96.96 on 6 March 2024, and spent much of mid-2024 above $60 before easing into the $40–$70 range by year-end.
In 2025, the stock remained volatile. It started the year just above $41, climbed into the mid-$40s in January, then trended lower, briefly dropping below $23 in April before recovering towards $30 by mid-year and finishing 2025 at $35.23. So far in 2026, VKTX has pulled back from late-December levels above $37, with the share price closing at $29.31 on 2 February 2026, leaving it modestly below levels seen in early February the previous year.
Past performance is not a reliable indicator of future results.
Viking Therapeutics (VKTX): Capital.com analyst view
Viking Therapeutics’ share price over the past two years has been marked by sharp rallies and equally notable pullbacks, reflecting the volatility commonly associated with clinical-stage biotech companies. Periods of strong gains have coincided with heightened interest in the company’s obesity and liver-disease pipeline, but these moves have also been followed by rapid reversals as traders reassessed trial updates, funding conditions and broader risk sentiment. While some market participants may interpret these swings as evidence of high growth potential, others view the same pattern as a reminder of the uncertainties surrounding clinical outcomes and regulatory milestones that can weigh on valuations.
Into early 2026, VKTX is trading below the peaks seen in 2024 and late 2025, with recent price action showing the shares slipping back under $30 after testing levels in the mid-$30s and above. For some, this retracement may be seen as a period of consolidation following earlier advances, while others may interpret it as the market demanding a greater margin of safety given the binary nature of drug-development catalysts and changing risk appetite within the biotech sector.
Summary – Viking Therapeutics 2026
- Viking Therapeutics (VKTX) is quoted on Capital.com as a stock CFD in US dollars, last trading near $29.11 with an intraday range of $28.92–$30.38 as of 2 February 2026 (4:36pm UTC).
- Over the past two years, VKTX has traded between the low-$20s and highs close to $97 in early 2024, before easing back into the $30–$40 area through late 2025 and slipping below $30 in early 2026.
- Recent technical readings show price trading below its main daily moving averages, with the 20-, 50-, 100- and 200-day SMAs clustered around the low- to mid-$30s and the 14-day RSI in lower-neutral territory, pointing to a weak trend structure.
- Commentary from external research and news sources continues to highlight Viking’s obesity and liver-disease pipeline, including VK2735 and VK2809, while also underlining the typical biotech risks associated with clinical data, regulation, funding requirements and sector-wide volatility.
Past performance is not a reliable indicator of future results.
FAQ
Who owns most of Viking Therapeutics’ stock?
Viking Therapeutics’ share register is dominated by institutional investors, reflecting its status as a US-listed clinical-stage biotechnology company. Large asset managers, specialist healthcare funds and biotechnology-focused investment firms account for a significant proportion of outstanding shares, alongside company insiders and retail investors. Ownership levels can change over time as funds rebalance portfolios or respond to clinical and corporate developments, so reported holdings should be viewed as snapshots rather than fixed positions.
What is the five-year Viking Therapeutics share price forecast?
There is no single, widely agreed five-year VKTX stock forecast. Most publicly available projections focus on 12-month horizons, while longer-term outlooks tend to vary significantly depending on assumptions around clinical trial outcomes, regulatory progress and funding needs. As a result, extended forecasts are inherently speculative and should be interpreted with caution, particularly given the binary nature of drug development and the historical volatility associated with biotech stocks.
Is Viking Therapeutics a good stock to buy?
Whether Viking Therapeutics is considered a 'good' stock depends on individual objectives, risk tolerance and market perspective. The company operates in high-demand therapeutic areas, which some participants view as offering long-term potential. At the same time, it remains a clinical-stage biotech business, meaning its valuation is sensitive to trial data, regulatory decisions and financing conditions. This combination can lead to sharp price movements in both directions, making the stock higher risk compared with more established companies.
Could Viking Therapeutics’ stock go up or down?
Viking Therapeutics’ share price can move both higher and lower, sometimes sharply, as it responds to news flow, clinical trial updates and broader market conditions. Positive data, strategic partnerships or favourable sentiment towards biotech can support upside, while trial delays, safety concerns or shifts in risk appetite can weigh on the price. Historical trading shows wide price ranges, underlining that outcomes are uncertain and that volatility is a defining feature of the stock.
Should I invest in Viking Therapeutics stock?
This article does not provide investment advice, and decisions about investing in Viking Therapeutics depend on personal circumstances and risk appetite. The stock’s performance is closely tied to future clinical results and regulatory milestones, which are uncertain by nature. Some market participants are attracted to this type of risk–reward profile, while others prefer assets with more predictable cash flows. Anyone considering exposure may choose to carry out independent research or seek professional advice.
Can I trade Viking Therapeutics CFDs on Capital.com?
Yes, you can trade Viking Therapeutics CFDs on Capital.com. Trading share CFDs lets you speculate on price movements without owning the underlying asset and to take long or short positions. However, contracts for difference (CFDs) are traded on margin, and leverage amplifies both profits and losses. You should ensure you understand how CFD trading works, assess your risk tolerance, and recognise that losses can occur quickly.